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Abstract
Background Proliferation and migration of retinal endothe-
lial cells (REC) are associated with the development of
proliferative diabetic retinopathy. REC proliferation is stim-
ulated by isoforms of vascular endothelial growth factor-A
(i.e., VEGF121 and VEGF165), basic fibroblast growth factor
(bFGF), and insulin-like growth factor (IGF-1) of which
VEGF165 also enhances migration of REC. Effects induced
by VEGF-A can be blocked with ranibizumab, a VEGF-
binding Fab fragment used in therapy of diabetic macular
edema. In this study, we investigated potential angiogenic
effects of placental growth factors (PlGF-1, PlGF-2) as other
members of the VEGF family and whether the primary
action of VEGF165 is modulated in the presence of bFGF,
IGF-1 and PlGF-1/-2. We also studied how effects of growth
factor combinations can be attenuated with ranibizumab.
Methods Effects of single growth factors or their combina-
tions on proliferation and migration of immortalized bovine
retinal endothelial cells (iBREC) were studied with or without
ranibizumab or the inhibitor of VEGF receptors KRN951.
Results Proliferation of iBREC was significantly stimulated
by 1–100 ng/ml PlGF-1 or PlGF-2, but additive effects were
not observed with various combinations of the tested growth
factors. Ranibizumab neutralized VEGF’s effect on prolifer-
ation but was not effective when the other growth factors
were used in combination with VEGF. bFGF and IGF-1 but
not PlGF-1 or PlGF-2 stimulated iBREC migration as single
agents, and they further enhanced VEGF-induced migration.
The effects of such growth factor combinations including
VEGF on migration were efficiently blocked by targeting
only VEGF with ranibizumab. Migration induced by VEGF
plus bFGF and IGF-1 was also almost completely inhibited
by KRN951 interfering with VEGF receptor signalling.
Conclusions Migration but not proliferation of iBREC induced
by combinations of bFGF, IGF-1, PlGF-1 or PlGF-2 together
with VEGF is efficiently suppressed by ranibizumab. VEGF-
mediated signalling through VEGFR2 seems to control REC
migration dominantly in the presence of other growth factors.
Keywords Retinal endothelial cells . Growth factors .
Ranibizumab . Migration . Proliferation . Proliferative
diabetic retinopathy
Introduction
Pathogenesis of diabetic retinopathy (DR) is associated with
deregulated expression of various growth factors of which
elevated levels were found in the vitreous fluid of DR patients
[1–4]. Appearance of diabetic macular edema (DME), observed
at any stage of DR, correlates with vascular endothelial growth
factor-A (VEGF) induced permeability of retinal endothelial
cells (REC) [5]. DME can be treated with the recently approved
VEGF-binding Fab-fragment ranibizumab or the recombinant
protein VEGF-trap/aflibercept binding also to placenta growth
factor (PlGF) [6–10]. VEGF inhibition might also be beneficial
to patients with proliferative DR (PDR), which can be conclud-
ed from evidence indicating that proliferation and migration of
REC associated with neovascularization is driven by angiogenic
growth factors: Both isoformsVEGF165 andVEGF121, aswell as
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PlGF-1 and basic fibroblast growth factor (bFGF) or insulin-like
growth factor-1 (IGF-1), stimulate proliferation of primary and
immortalized REC of bovine or human origin over a wide range
of concentrations including physiological conditions [11–16].
Migration of immortalized and primary bovine REC ((i)BREC)
is induced by VEGF165 but not by VEGF121 [11, 14]. VEGF is
only very weakly expressed by immortalized or primary BREC,
but its secretion can be slightly enhanced with bFGF together
with IGF-1 [17, 18]. BREC also express PlGF-1 which can be
stimulated by binding of VEGF to VEGF receptor (VEGFR) 2
[19, 20]. In addition to VEGFR2, VEGFR1 and neuropilin 1
(NRP-1) are REC-expressed receptors that are activated by
members of the VEGF family [17, 21]. VEGF165 and
VEGF121 efficiently trigger signalling through VEGFR1 and
VEGFR2 [22]. NRP-1 is a potent receptor for VEGF165, and is
only weakly activated by VEGF121 [23, 24]. Both isoforms
PlGF-1 and PlGF-2 bind to VEGFR1, but PlGF-2 also to
NRP-1 [25–27].
Based on this experimental evidence and clinical obser-
vations, we studied the effects on proliferation and migration
of iBREC (and their potential inhibition by ranibizumab) of
combinations of involved growth factors (VEGF121, PlGF-1,
PlGF-2, bFGF, and IGF-1) in concert with VEGF165. The
well-established model of iBREC was used in view of its
distinct advantages over primary cells or rodent models:
compared to primary cells, it is a distinct advantage of
iBREC that these are free of contaminating cells of other
types. Although iBREC are of bovine origin, they behave
like primary human retinal EC (HREC): their proliferation
can be stimulated similarly with VEGF-A, IGF-1 or bFGF
[13–16]. Involved bovine proteins also show a high similar-
ity to their human counterparts. Our systematic approach
including all candidate factors was chosen to reveal their
relative contributions to DR pathophysiology with immedi-
ate consequences for therapies targeting VEGF.
Materials and methods
Reagents
Recombinant human growth factors bFGF, IGF-1, PlGF-1
(all E.coli-expressed) and rhVEGF165 (SF21-expressed) were
purchased from R&D Systems (Wiesbaden, Germany),
rhVEGF121 (SF21-expressed) from Calbiochem (Merck,
Darmstadt, Germany), and PlGF-2 (E.coli-expressed) from
PeproTech (Hamburg, Germany). Recombinant viral VEGF-
E binding to VEGFR2 and NRP, was from Abcam
(Cambrigde, UK) [28]. The modified Fab fragment
ranibizumab (Lucentis, 10 mg/ml) of a humanized VEGF-
binding antibody was a gift from Novartis Pharma GmbH
(Nuremberg, Germany) [6]. N-(2-Chloro-4-((6,7-dimethoxy-
4-quinolyl)oxy)phenyl)-N ′-(5-methyl-3-isoxazolyl)urea
(KRN951), a tyrosine kinase inhibitor specific for VEGFR1
and VEGFR2, was from Calbiochem [29].
Cell cultivation
Telomerase-immortalized microvascular endothelial cells from
bovine retina (iBREC) were cultivated in endothelial cell
growth medium (ECGM hHC; Promocell, Heidelberg,
Germany) supplemented with 0.4 % endothelial cell growth
supplement/H (ECGS/H), 10 ng/ml epidermal growth factor,
2.8 μM hydrocortisone, and 5 % fetal calf serum (FCS) as
previously described [13, 14]. Cells used in the experiments
had a history of 20–40 passages from the stage of primary
culture. Their stable expression of marker proteins specific for
endothelial cells (i.e., von Willebrand factor, vascular endothe-
lial cadherin, claudins, VEGF receptors) had been confirmed
[13, 14, 17].
Cell proliferation assay
In a 96-well plate, 5×103 iBREC in ECGM-nHC (like
ECGM-hHC but with 103 nM hydrocortisone) were allowed
to attach to the fibronectin-coated (50 μg/ml; BD Biosciences,
Heidelberg, Germany) bottom of a cavity overnight. The
medium was then changed to EBGM-nHC (same as ECGM-
nHC but 0.25 % FCS). After cultivation for 24 h, cells were
exposed to growth factors VEGF165, VEGF121, VEGF-E,
PlGF-1, PlGF-2, bFGF, or IGF-1, applied as single agents or
in various combinations at 10 ng/ml each, and 100 μg/ml
ranibizumab in serum-free medium for 24 h. Enzymatic con-
version ofWST-1 (RocheDiagnostics,Mannheim, Germany),
indicative of proliferating cells, was then measured according
to the manufacturer’s protocol in 16 replicate wells [14].
Values were normalized in relation to those obtained with
control cells not treated with effectors. Results were shown
only of experiments in which iBREC were treated with
growth factors for up to 24 h, because additional effects were
not observed during prolonged exposure.
Cell migration assay
Transmembrane cell migration assays were performed in a
modified Boyden chamber consisting of 12-well cell culture
plates and inserts with a porous membrane (pore size 8.0 μm,
∅1 cm; BD Biosciences). Their lower compartments were
filled with EBGM-nHC without ECGS/H and FCS but con-
taining 5 μg/ml fibronectin, growth factors (VEGF165,
VEGF121, VEGF-E, PlGF-1, PlGF-2, bFGF or IGF-1, ap-
plied as single agents or in various combinations at 25 ng/ml
each) and/or 60 μg/ml ranibizumab. Inserted membranes
were initially incubated for 1 h at 37 °C before 400 μl
EBGM-nHC (without ECGS/H and FCS) and a suspension
of 105 iBREC in 100 μl of this medium were added
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subsequently to the upper compartment. After 20 h at 37 °C,
migration of cells through the pores of the membrane was
assessed as described [14]. Cells remaining on top of the
membrane were scraped off, and cells which had migrated to
the lower surface of the membrane were fixed in methanol at
−20 °C for 15 min. Nuclei of migrated cells were stained by
mounting the membrane in VectaShield-DAPI, and visual-
ized by fluorescence microscopy. Cells were counted in
triplicate wells in four randomly chosen microscopic fields.
Values were normalised to those obtained with control cells
not treated with effectors. To investigate specific inhibition
of VEGF receptors, 10 nM KRN951 dissolved in DMSO (or
only the solvent in control experiments) was added to the
medium in both compartments.
General considerations and statistical analyses
Controls were treated in exactly the same way with medium
lacking the effectors. All experiments were repeated several
times, and in each experiment data were collected from
multiple replicates. The Mann–Whitney U test was used to
compare two sets of experimental data and differences
resulting in p-values below 0.05 were considered significant.
To compare several groups representing effector-treated
cells, also the Kruskal–Wallis test was used. Shown results
represent several independent experiments and are visual-
ized as conventional box-whiskers diagrams, with the mid-
dle line representing the mean and the boundaries of the
boxes the 75 % and 25 % percentiles, or the mean and
standard deviations are provided.
Results
Effects of different growth factors were studied under exper-
imental conditions which were defined by important previ-
ous observations: The concentrations of growth factors (10
to 25 ng/ml), in a range similar to that measured in the
vitreous fluid of DR patients, were found to be sufficient
for specific and strong stimulation of proliferation or migra-
tion of REC [1–4, 11–16]. Specific inhibition of VEGF-
induced iBREC proliferation or migration without affecting
basal processes was observed with (therapeutically achiev-
able) 100 or 60 μg/ml ranibizumab respectively [7, 14].
Proliferation stimulated by VEGF in combination
with other growth factors is not inhibited by ranibizumab
In this study we focused on other members of the VEGF
family, PlGF-1 and PlGF-2 as well as VEGF-E which acts
mainly through the receptors VEGFR2 and NRP-1. In addi-
tion to potential stimulation of iBREC proliferation, possible
additive effects of the growth factors were investigated. All
members of the VEGF family significantly stimulated prolif-
eration to a similar extent at concentrations between 1 and
100 ng/ml after incubation for 24 h (Fig. 1). Proliferation was
also enhanced by exposure of iBREC to various growth factor
combinations applied at moderate concentrations of 10 ng/ml
each (Table 1). VEGF-E showed a similarly strong effect at all
concentrations tested, whereas maximum stimulation was
seen below the highest concentrations with PlGF-1 (at 1 and
10 ng/ml) or PlGF-2 (at 1 ng/ml; Fig. 1). Additive effects of
Fig. 1 VEGF-E, PlGF-1 and PlGF-2 stimulate proliferation of iBREC.
Serum-starved iBREC were incubated with 1 to 100 ng/ml of VEGF-E
(a), PlGF-1 (b) or PlGF-2 (c), and proliferation was measured as
described in Materials and Methods
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growth factor combinations were not observed (Table 1). To
investigate whether VEGF inhibition is sufficient to block
surplus iBREC proliferation caused by different growth fac-
tors, experiments were also performed in the presence of
100 μg/ml ranibizumab which binds all isoforms of VEGF-
A. When single growth factors were used, ranibizumab only
inhibited proliferation of iBREC induced by VEGF165 or
VEGF121, but not by PlGF-1/2, bFGF or IGF-1, confirming
the specificity of the Fab-fragment ([14], data not shown).
Accordingly, substantial inhibition of proliferation was not
achieved by treatment with ranibizumab when cells were
exposed to combinations of growth factors including VEGF
(Table 1).
PlGF does not induce migration of iBREC
We have already demonstrated that migration of iBREC
is stimulated by 10 to 100 ng/ml VEGF165 but not by
VEGF121, and that VEGF-induced migration is specifi-
cally and completely inhibited by 60 μg/ml ranibizumab
[14]. Similar to their reported effect on primary BREC,
PlGF-1 or PlGF-2 failed to stimulate iBREC migration
(Fig. 2a) [11]. Interestingly, migration stimulated by
VEGF165 is further enhanced in the presence of the
other growth factors, despite their inactivity as single
agents. The impact of viral VEGF-E was studied be-
cause this protein activates only the VEGF receptors
VEGFR2 and NRP-1, which seems to be sufficient to
induce migration of iBREC, and VEGF-E was slightly
more potent than VEGF165 (Fig. 2a).
Considering the key role of VEGF165 in stimulation
of iBREC migration, we hypothesized that its inhibition
with ranibizumab might normalize migration even in the
presence of PlGFs. Indeed, 60 μg/ml ranibizumab
completely blocked effects on iBREC migration under
these conditions (Fig. 2b).
bFGF and IGF-1 enhance migration of iBREC
We also investigated whether bFGF and IGF-1, angiogenic
growth factors not belonging to the VEGF family, enhanced
migration of iBREC. Migration of iBREC was strongly
stimulated by bFGF and weaker by IGF-1, but additive
effects of both factors were not observed (Fig. 3). As
expected for a VEGF-binding Fab fragment, bFGF-
stimulated migration was not inhibited by ranibizumab. It
did, however, significantly reduce iBRECmigration induced
by IGF-1 (Fig. 3).
Migration stimulated byVEGF in combination with other growth
factors is efficiently inhibited by ranibizumab
Migration of iBREC was measured in the presence of vari-
ous combinations of the six growth factors used in this study
to investigate potential additive effects of their concerted
actions. bFGF but not IGF-1 significantly enhanced the
stimulation of VEGF165 on iBREC migration. Further addi-
tion of IGF-1, VEGF121, and/or PlGFs did not amplify the
impact of VEGF165 together with bFGF (Fig. 4a).
Co-stimulation of migration with VEGF165 and bFGF was
partly inhibited with ranibizumab targeting the VEGF-A
isoforms, whereas complete inhibition by ranibizumab was
seen when VEGF165 was supplemented with IGF-1 (Fig. 4b).
In addition, migration induced by the collective action of all
growth factors tested was almost completely restrained by
ranibizumab (Fig. 4b). Even co-stimulation with bFGF and
IGF-1 in the presence of VEGF121 (196 % ± 30 % relative to
controls), which is inactive as a single factor, was suppressed
Table 1 Proliferation of iBREC stimulated by growth factor combina-
tions including VEGF is only partly inhibited by ranibizumab. Serum-
starved iBREC were stimulated with growth factors (10 ng/ml each)
with or without 100 μg/ml ranibizumab for 24 h before conversion of
WST-1 was determined as a measure of proliferation. Values were
normalized in relation to those obtained with untreated cells




Comparison GF(s) to GF(s)
with ranibizumab
– – – – – – X 1.07±0.22 p>0.05
X X X X – – – 1.26±0.17 p<0.0001
X X X X – – X 1.13±0.22 p=0.0092 p=0.0084
X – – – X X – 1.46±0.21 p<0.0001
X – – – X X X 1.33±0.17 p<0.0001 p=0.0139
X X – – X X – 1.33±0.22 p<0.0001
X X – – X X X 1.21±0.21 p=0.0002 p=0.0255
X X X X X X – 1.26±0.14 p<0.0001
X X X X X X X 1.14±0.22 p<0.0001 p>0.05
GF growth factor
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by ranibizumab to basal migration (91 % ± 50 % relative to
controls; all differences significant with p<0.0003).
Specific blocking of VEGFR1/R2 efficiently prevents
migration stimulated by combinations of VEGF
with other growth factors
Our observation that VEGF-inhibition efficiently blocked
iBREC migration stimulated by combined action of bFGF,
IGF-1 and VEGF165 suggested a dominant role of VEGF165
which activates signalling through its receptors VEGFR1, -
R2, und NRP-1. Therefore, we investigated whether blocking
the tyrosine kinase activities of VEGFR1 and -R2 with the
specific inhibitor KRN951 is a sufficient alternative to inhibit
migration under these conditions (Fig. 5). This was confirmed
by experiments showing that KRN951 almost completely
inhibited migration stimulated by VEGF165 plus bFGF and
IGF-1. All our results support a dominant role of VEGF sig-
nalling through the VEGF receptors in stimulation of iBREC
migration.
Discussion
We investigated the effects of a collection of growth factors
potentially involved in the control of proliferation and mi-
gration in retinal endothelial cells, the key processes in PDR-
associated neovascularization. To evaluate the potential of
VEGF inhibition to counteract neovascularization even in
the presence of other stimulating factors, VEGF-binding
ranibizumab was included in the experiments.
All six growth factors tested stimulated proliferation of
iBREC, but only VEGF165, bFGF, and IGF-1 also enhanced
migration (see also Table 2). That PlGFs only stimulated
proliferation was also observed in experiments with primary
BREC [11]. However, the proposed action of PlGFs through
mobilization of VEGF seems unlikely because PlGF-stimu-
lated proliferation of iBRECwas not inhibited by ranibizumab
[24]. iBREC proliferation induced by co-stimulating growth
factors including VEGF165 was not completely inhibited by
the Fab fragment, suggesting parallel activation of indepen-
dent signalling pathways. This assumption was supported by
previous studies also indicating that incomplete inhibition of
VEGF165-induced proliferation by the anti-VEGF antibody
bevacizumab might be due to VEGF-upregulated PlGF [15,
19, 30]. Such possibly persistent induction of PlGFs or other
pro-proliferative factors might play a role in PDR that weakly
respond to anti-VEGF therapies. However, proliferation stim-
ulated by PlGF in combination with VEGF can most likely be
completely inhibited by VEGF trap because it also binds to
PlGF [8, 9, 31]. Whether this is sufficient to block
Fig. 3 bFGF and IGF-1 enhance iBREC migration. Migration of
iBREC towards fibronectin and bFGF and/or IGF-1 (25 ng/ml each)
in the absence or presence of 60 μg/ml ranibizumab was measured by a
modified Boyden Chamber assay. Strong stimulation of migration by
bFGF was not blocked by ranibizumab, whereas the IGF-1-induced
effect was inhibited
Fig. 2 PlGFs do not promote migration of iBREC. Migration of
iBREC over 24 h towards fibronectin and VEGF165, VEGF121, PlGF-
1, PlGF-2 or VEGF-E (25 ng/ml each) as single agents or in combina-
tion was measured by a modified Boyden Chamber assay in the absence
(a) or presence (b) of 60 μg/ml ranibizumab. a VEGF165 and viral
VEGF-E, but not PlGF-1 or PlGF-2 significantly stimulated migration.
b Migration induced by treatment with a mixture of VEGF165,
VEGF121, PlGF-1, and PlGF-2 was strongly inhibited by ranibizumab.
GF growth factor mix containing VEGF165, VEGF121, PlGF-1, and
PlGF-2
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proliferation stimulated by a combination together with bFGF
and IGF-1 remains to be shown.
In contrast to its co-stimulation of REC proliferation,
VEGF165 seems so dominant in the regulation of migration
that—despite some effects contributed by other growth fac-
tors observed in this study and by others—induced migration
was almost completely suppressed by ranibizumab, even in
experiments with the most complex combinations of factors.
The dominant role of VEGF165 was confirmed by our obser-
vation that the inhibitor of VEGFR KRN951 also blocked
iBREC migration stimulated by a mixture of VEGF165,
bFGF, and IGF-1. At the concentration used in this study,
KRN951 specifically inhibits the tyrosine kinase activity of
VEGFR1 and -R2 without affecting other receptor tyrosine
kinases [29]. Interestingly, migration stimulated by VEGF121
together with bFGF and IGF-1 was totally blocked by
ranibizumab, although bFGF-induced migration was not
affected, and VEGF121 by itself did not even enhance
iBREC migration. There is some evidence supporting the
concept that bFGF facilitates binding of VEGF121 by its
induction of VEGFR2 expression [32]. Then migration
may be essentially driven by VEGF121, and its removal with
ranibizumab might be sufficient to normalize migration.
Migration of (i)BRECwas not induced by PlGF-1/-2, which
is in contrast to the observation that these growth factors
strongly stimulate migration of macrovascular endothelial cells
Fig. 5 Specific interference with VEGFR1/R2 signalling blocks stim-
ulated iBREC migration. Migration of iBREC over 24 h towards
fibronectin and growth factors (VEGF165 or VEGF165 plus bFGF and
IGF-1) was measured by a modified Boyden Chamber assay with or
without 10 nM KRN951. This VEGFR inhibitor almost completely
inhibited migration induced by the three factors. GF growth factors
Fig. 4 Migration stimulated by
growth factor combinations is
inhibited by ranibizumab.
Migration of iBREC over 24 h
towards fibronectin and
VEGF165, VEGF121, PlGF-1,
PlGF-2, bFGF and IGF-1
(25 ng/ml each) in various
combinations was measured by
a modified Boyden Chamber
assay without (a) or with (b)
60 μg/ml ranibizumab. a VEGF
in combination with either
bFGF plus IGF-1 or PlGFs
stimulated iBREC migration
significantly stronger than
VEGF165 alone. b Migration
induced by combination of all
growth factors including
VEGF165 was strongly inhibited
by ranibizumab. GF growth
factors
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of the human umbilical vein (HUVEC) [31]. However, both
isoforms stimulated proliferation of iBREC, thereby confirming
that the used recombinant human polypeptides can activate the
relevant bovine receptor VEGFR1. Another example for the
obviously different behavior of macrovascular and microvas-
cular EC is the observation that VEGF121 induces migration of
HUVEC, whereas iBREC do not respond [14, 24]. Basic
differences between HUVEC and HREC in their expression
of genes important for angiogenic processes were also shown
by expression profiling [33].
Neovascularization requires migration and proliferation
of REC, but therapeutic interference with only one of these
processes might not be enough to prevent this hallmark of
PDR. Results of several studies based on in-vitro or in-vivo
models indeed suggest that more than inhibition of VEGF
(which is not the only factor controling REC proliferation) is
needed to suppress neovascularization. In an in-vitro model,
sprouting of EC was stronger inhibited when bFGF was
targeted in addition to VEGF [34]. Efficient suppression of
retinal neovascularization was also achieved with VEGF-
trap, a chimeric recombinant protein consisting of the
VEGF-binding domains of VEGFR1 and -R2 that inhibits
VEGF as well as other members of the protein family such as
PlGFs [8, 9]. This therapeutic effect is most likely due to
inhibition of PlGF-driven proliferation of REC.
Our results also suggest that different VEGF receptors
(VEGFR1, -R2, and/or NRP-1) are involved in the processes
leading to altered proliferation and migration of iBREC
(Table 2): all members of the VEGF family tested—VEGF165,
VEGF121, PlGF-1, PlGF-2, and VEGF-E—stimulated
proliferation, suggesting that activation of either receptor
is sufficient, which is in accordance with other studies using
EC from various sources [35]. In contrast, binding of a ligand
to VEGFR2 and to NRP-1 seems to be necessary to enhance
migration, because only VEGF165 and VEGF-E, but not
VEGF121 were efficient stimulators. Because VEGF-E was
most efficient in stimulating migration of iBREC, one could
assume that VEGFR1 is a negative regulator. But combined
activation of VEGFR1 and -R2 by VEGF165/121 plus PlGF-1/-2
did not result in a lower migration rate compared to stimulation
with VEGF165 alone. More likely, different receptors
compete for the available factors, and VEGFR2-mediated
signalling is the most efficient pathway leading to enhanced
migration. The results of our experiments with immortalized
BREC support the assumption that VEGFR2 is crucially
involved in signal transduction in EC from various species
and different tissues [35]. Although VEGFR1 can play an
important role in EC proliferation, its contribution to other
cellular processes stimulated by VEGF is still unclear:
potentiating the effect of VEGF by cross-activation of
VEGFR2 through VEGFR1 in response to stimulation with
PlGF has been reported thereby [35]. In contrast, activated
VEGFR1 was also reported to be a negative regulator of
VEGFR2 signaling in the event that VEGFR2 had been
activated first [21]. However, binding of both receptors by
a combination of VEGF and PlGF did not markedly affect
VEGF-induced iBREC proliferation or migration.
Whereas stimulation of migration by the concerted action
of growth factors can be at least partly prevented by
ranibizumab, substantial inhibition of proliferation was not
observed in such experimental setting. Both proliferation
and migration of REC are required for neovascularization
observed in PDR, and it will be interesting to learn from the
ongoing clinical trials whether inhibition of one of these
processes by ranibizumab can delay or slow down progression
of the disease. The possible surplus benefit of inhibiting all
VEGF family members by VEGF-trap remains to be shown,
and in view of our results, additional targeting of bFGF and
IGF-1 might be considered a more promising approach in the
therapy of PDR [9, 34]. However, these growth factors are
also involved in retinal neuroprotection, and their complete
inhibition might be detrimental to the function of retinal cells
[36–38]. Moderate instead of complete depletion of these
growth factors might therefore be more promising, although
complete inhibition or reversal of pathological processes may
not be achieved under these conditions.
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Table 2 Receptor usage of
VEGF family members and
summary of their effects on
iBREC proliferation and
migration
+ binding and activation of
receptor
Ligands VEGF repceptors Stimulation of
VEGFR1 VEGFR2 Neuropilin-1 proliferation migration
VEGF-A
VEGF121 + + −/+ Yes No
VEGF165 + + + Yes Yes
PlGF
PlGF-1 + Yes No
PlGF-2 + + Yes No
VEGF-E + + Yes Yes
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